Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
January 03 2018 - 9:55PM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf
T-cell immunotherapy company developing novel treatments for
patients with cancer, autoimmune and viral diseases, today
announced the pricing of an underwritten public offering of
7,000,000 shares of its common stock at a price to the public of
$18.25 per share. The gross proceeds from this offering are
expected to be $127,750,000, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by Atara Biotherapeutics. The offering is expected to close on or
about January 8, 2018, subject to customary closing conditions. In
addition, Atara Biotherapeutics has granted the underwriters a
30-day option to purchase up to an additional 1,050,000 shares of
its common stock at the public offering price, less the
underwriting discounts and commissions.
J.P. Morgan and Cowen are acting as joint book-running managers
for the proposed offering. William Blair & Company, L.L.C. and
Canaccord Genuity Inc. are acting as co-managers.
The shares described above are being offered by Atara
Biotherapeutics pursuant to a shelf registration statement on Form
S-3, including a base prospectus, that was previously filed by
Atara Biotherapeutics with the Securities and Exchange Commission
(the “SEC”) on November 9, 2015 and became effective on November
23, 2015. A preliminary prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC,
and a final prospectus supplement and accompanying prospectus
related to the offering will be filed with the SEC and will be
available on the SEC’s website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus related to this offering, when available, may be
obtained from J.P. Morgan, by mail at J. P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by telephone at 866-803-9204; or from Cowen,
by mail at Cowen and Company, LLC, c/o Broadridge Financial
Services, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717 or by telephone at
631-274-2806.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
About Atara Biotherapeutics, Inc. Atara
Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy
company developing novel treatments for patients with cancer,
autoimmune and viral diseases.
Forward-Looking Statements This press release
contains or may imply “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. For example,
forward-looking statements include statements regarding: the
completion of the proposed public offering. These statements
are subject to various risks and uncertainties, actual results
could differ materially from those projected and Atara
Biotherapeutics cautions investors not to place undue reliance on
the forward-looking statements in this press release. These risks
and uncertainties include, without limitation, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering. There
can be no assurance that Atara Biotherapeutics will be able to
complete the public offering on the anticipated terms, or at all.
Risks and uncertainties relating to Atara Biotherapeutics and its
business can be found under the heading “Risk Factors” in Atara
Biotherapeutics’ quarterly report on Form 10-Q filed with the SEC
on November 9, 2017, and in the preliminary prospectus supplement
related to the proposed offering filed with the SEC on January 2,
2018. Except as otherwise required by law, Atara Biotherapeutics
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date hereof,
whether as a result of new information, future events or
circumstances or otherwise.
INVESTOR & MEDIA CONTACTS:
Investors: John Craighead, Atara
Biotherapeutics 650-410-3012 jcraighead@atarabio.com
Steve Klass, Burns McClellan 212-213-0006 x331
sklass@burnsmc.com
Media: Justin Jackson, Burns McClellan
212-213-0006 x327 jjackson@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024